You are here: Industry Insights > Jivi

News List

Two lots of Kogenate® recalled due to mislabelling europeanpharmaceuticalreview
July 25, 2019
Two lots of Kogenate® FS vials actually contain the FVIII hemophilia A treatment, Jivi®.
Bayer's Jivi approved in Europe for previously treated haemophilia A pharmafile
November 29, 2018
Bayer has revealed that its recombinant Factor VIII (rFVIII) replacement therapy Jivi, also known as BAY94-9027, has received approval from the European Commission for the treatment...
EU gives Bayer's Jivi the green light November 29, 2018
Jivi (formerly BAY94-9027) has been approved by the European Commission for the treatment and prophylaxis of bleeding in previously treated patients 12 years of age or older...
Bayer Inc. receives approval for hemophilia A treatment Jivi firstwordpharma
October 25, 2018
Bayer Inc. receives approval for hemophilia A treatment Jivi
Bayer wins US nod for Jivi pharmatimes
September 14, 2018
US regulators have approved Bayer’s Jivi (formerly BAY94-9027), a longer-acting Factor VIII therapy designed to reduce the number of infusions...
Bayer Receives FDA Approval for Jivi americanpharmaceuticalreview
August 31, 2018
Bayer announced the U.S. Food and Drug Administration (FDA) has approved Jivi (BAY94-9027, antihemophilic factor [recombinant] PEGylated-aucl) for the routine prophylactic treatment of hemophilia A in previously treated adults and adolescents 12 years of